儿童噬血细胞性淋巴组织细胞增生症的预后因素分析

陆文娴; 罗建明

PDF(1053 KB)

中国当代儿科杂志 ›› 2012, Vol. 14 ›› Issue (08) : 593-597.

论著·临床研究

儿童噬血细胞性淋巴组织细胞增生症的预后因素分析

陆文娴，罗建明

作者信息 +

Prognostic factors for hemophagocytic lymphohistiocytosis in children

LU Wen-Xian, LUO Jian-Ming

Author information +

文章历史 +

摘要

目的：通过总结儿童噬血细胞性淋巴组织细胞增生症(HLH)的临床特征，分析相关因素与预后的关系，探索影响HLH患儿预后的因素。方法：回顾性分析63例HLH患儿的病例资料，使用Kaplan-Meier法绘制生存曲线，采用COX模型对影响预后的相关因素进行单因素分析，筛选出有意义的因素进行多因素COX回归分析。结果：患儿的3年及5年生存率均为62.9%；确诊后第1天至4个月，生存率由98.4%降至73.2%。影响疾病预后单因素分析中，具有统计学意义的因素只有治疗后2~3周血小板恢复情况（P=0.002）；在使用依托泊苷治疗的患儿中，治疗1 d后体温恢复情况对预后的影响具有统计学意义（P=0.016）。结论：HLH患儿的预后较为满意，但确诊后的前4个月生存率下降快。治疗2~3周后血小板恢复情况以及使用依托泊苷1 d后体温恢复情况影响患儿预后。

Abstract

OBJECTIVE: To study the main factors influencing prognosis of hemophagocytic lymphohistiocytosis (HLH) in children by summarizing the clinical features of HLH and investigating the relationship between relevant factors and prognosis. METHODS: The medical data of 63 children with HLH were retrospectively reviewed. Kaplan-Meier method was employed to draw survival curves. Factors influencing prognosis were assessed with Cox univariate analysis, and Cox multivariate analysis was done on statistically significant factors. RESULTS: The 3-year and 5-year survival rates were both 62.9%. The survival rate decreased from 98.4% at 1 day after definite diagnosis to 73.2% at 4 months. Univariate analysis demonstrated only one factor, which was that the condition of platelet recovery after treatment of 2 to 3 weeks was significantly related to prognosis (P=0.002). In children receiving etoposide therapy, temperature recovery after one day of treatment was significantly related to prognosis (P=0.016). CONCLUSIONS: Children with HLH have a satisfactory prognosis, but the survival rate reduces rapidly in the first 4 months after definite diagnosis. Platelet recovery after treatment of 2 to 3 weeks and temperature recovery after one day of treatment are factors influencing prognosis of HLH in children.

导出引用

陆文娴，罗建明. 儿童噬血细胞性淋巴组织细胞增生症的预后因素分析[J]. 中国当代儿科杂志. 2012, 14(08): 593-597

LU Wen-Xian, LUO Jian-Ming. Prognostic factors for hemophagocytic lymphohistiocytosis in children[J]. Chinese Journal of Contemporary Pediatrics. 2012, 14(08): 593-597

中图分类号： R725.5

参考文献

［1］Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management［J］. Clin Exp Immunol, 2011, 163(3): 271-283.

［2］Henter JL, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis［J］. Pediatr Blood Cancer, 2007, 48(2): 124-131.

［3］Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis［J］. Acta Paediatr Scand, 1991, 80（4）: 428-435.

［4］Janka GE. Familial hemophagocytic lymphohistiocytosis［J］. Eur J Pediatr, 1983, 140(3): 221-230.

［5］Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection-and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis［J］. Hematol Oncol Clin North Am, 1998, 12(2): 435-444.

［6］广东省小儿噬血细胞综合征协作组.儿童噬血细胞综合征68例临床研究［J］. 中国小儿血液与肿瘤杂志, 2009, 14(1): 20-22.

［7］Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol［J］. Blood, 2011, 118(17): 4577-4584.

［8］Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis［J］. Eur J Pediatr, 2007, 166(2): 95-109.

［9］Ramachandran B, Balasubramanian S, Abhishek N, Ravikumar KG, Ramanan AV. Profile of hemophagocytic lymphohistiocytosis in children in a tertiary care hospital in India［J］. Indian Pediatr, 2011, 48(1): 31-35.

［10］Kim HK, Kim HG, Cho SJ, Hong YM, Sohn S, Yoo ES, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease［J］. Pediatr Hematol Oncol, 2011, 28(3): 230-236.

［11］石杨，王丽杰.小儿噬血细胞综合征临床特点及预后危险因素分析［J］. 中国现代医学杂志, 2011, 21（5）:645-651.

［12］Janka GE, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis［J］. Br J Haematol, 2004, 124(1): 4-14.

［13］Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associated with haemophagocytic syndrome［J］. Rev Med Virol, 2010, 20(2): 93-105.

［14］Tang YM, Xu XJ. Advances in hemophagocytic lymphohistiocytosis: pathogenesis, early diagnosis/differential diagnosis, and treatment［J］. Sci World J, 2011, 11(3): 697708.

［15］Imashuku S, Hyakuna N, Funabiki T, Ikuta K, Sako M, Iwai A, et al. Low natural killer activity and central nervous system disease as a high-risk prognostic indicator in young patients with hemophagocytic lymphohistiocytosis［J］. Cancer, 2002, 94(11): 3023-3031.

［16］王冠玲,胡群,张柳清,刘爱国,刘双又,张耀东,等.儿童噬血细胞综合征死亡相关因素分析［J］.临床儿科杂志,2010,28(5):438-441.

［17］Horne A, Trottestam H, Aricò M, Egeler RM, Filipovich AH, Gadner H, et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis ［J］. Br J Haematol, 2008, 140(3): 327-335.

［18］Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan［J］. Int J Hematol, 2007, 86(1): 58-65.

［19］金颖康,谢正德,杜忠东,杨双,申昆玲.儿童Epstein-Bar病毒相关性噬血细胞性淋巴组织细胞增生症的回顾性分析［J］.首都医科大学学报, 2010, 31(2):192-196.

［20］Imashuku S, Teramura T, Tauchi H, Ishida Y, Otoh Y, Sawada M, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis［J］. Haematologica, 2004, 89(2): 183-188.

［21］Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis［J］. Crit Rev Oncol Hematol, 2002, 44(3): 259-272.